Background: Hepatocellular carcinoma (HCC) is one of the most common primary hepatic malignancies and growing challenges of global health. In this study, for the first time in Iran, we investigated the 5-year survival rate and prognostic factors in patients with HCC.
Materials and methods: In this historical cohort study, we examined the medical records of 227 HCC patients who were registered in the central tumor registry of our institution from September 2007 to September 2017. Demographic data, clinical parameters, received treatments, and survival curves from time of diagnosis were evaluated. Kaplan-Meier was used for univariate analysis, and multivariable analysis was performed by Cox regression.
Results: A total of 208 (91.63%) patients were dead. The 5-year survival rate was estimated 19 (8.37%). The average follow-up in this study was 14.3 months. Overall median survival rate was 12.1 months. Univariate analysis showed that tumor size, metastasis, number of involved lymph node, hepatitis type, and treatment were significantly related to the survival rate, and Cox regression analysis revealed that the tumor size >3 cm (hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.68-4.97; P = 0.027), involved lymph nodes >2 (HR = 4.12, 95% CI = 2.66-6.38; P = 0.001), metastasis (HR = 3.87, 95% CI = 3.13-6.54; P = 0.011), combination therapy with surgery and chemotherapy (HR = 0.4, 95% CI = 0.15-0.79; P = 0.023), and coinfection with hepatitis B virus and hepatitis C virus (HR = 2.11, 95% CI = 1.81-4.6; P = 0.036) are the most relevant prognostic factors with 5-year survival rate in patients with HCC.
Conclusion: Results of this study will help estimate survival rates for patients with HCC according to their clinical status.
Keywords: Five-year survival rate; hepatocellular carcinomas; prognostic factors.
Copyright: © 2019 Journal of Research in Medical Sciences.
Conflict of interest statement
There are no conflicts of interest.
Comparison between disease free survival of hepatocellular carcinoma after hepatic resection in chronic hepatitis B patients with or without cirrhosis.J Med Assoc Thai. 2015 Apr;98(4):334-42. J Med Assoc Thai. 2015. PMID: 25958707
Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.World J Surg Oncol. 2016 Apr 2;14:100. doi: 10.1186/s12957-016-0855-z. World J Surg Oncol. 2016. PMID: 27038790 Free PMC article.
Hepatitis B and C viruses and survival from hepatocellular carcinoma in the Arkhangelsk region: a Russian registry-based study.Int J Circumpolar Health. 2013 May 13;72:20282. doi: 10.3402/ijch.v72i0.20282. Print 2013. Int J Circumpolar Health. 2013. PMID: 23687637 Free PMC article.
Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation.J Cancer Res Clin Oncol. 2018 Dec;144(12):2465-2474. doi: 10.1007/s00432-018-2756-8. Epub 2018 Sep 26. J Cancer Res Clin Oncol. 2018. PMID: 30259149 Free PMC article.
Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.Drug Des Devel Ther. 2015 Aug 10;9:4431-40. doi: 10.2147/DDDT.S86629. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26309396 Free PMC article. Review.
- Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: A review of available epidemiological data. J Hepatol. 2013;58:593–608. - PubMed
- Franceschi S, Raza SA. Epidemiology and prevention of hepatocellular carcinoma. Cancer Lett. 2009;286:5–8. - PubMed
- Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, et al. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: An analysis of 1066 cases of a German HCC registry. J Clin Gastroenterol. 2014;48:279–89. - PubMed